Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

Study n Study design Jadad score Therapy period Follow-up period Therapy regimen
Lau G.K.K. 2005 814 RCT 4 48 w 24 w 1. PEG-IFNα-2a (180 ug/w) + placebo
2. PEG-IFNα-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Marcellin P. 2004 537 RCT 4 48 w 24 w 1. PEG-IFNα-2a (180 ug/w) + placebo
2. PEG-IFNα-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Marcellin P. 2009 315 RCT 4 48 w 3 y 1. PEG-IFNα-2a (180 ug/w) + placebo
2. PEG-IFNα-2a (180 ug/w) + LAM (100 mg/d)
3. LAM (100 mg/d)
Chan H.L.Y.1 2005 100 RCT 3 52-60 w 24 w 1. PEG-IFNα-2b (1.5 ug/kg, 1/w, Wt < 65 kg; 100 ug/w, Wt ≥ 65 kg) 8 w → PEG-IFNα-2b + LAM 24 w → LAM 28 w
2. LAM (100 mg/d)
Chan H.L.Y.2 2005 95 RCT 3 52-60 w 3 y 1. PEG-IFNα-2b (1.5 ug/kg, 1/w, Wt < 65 kg; 100 ug/w, Wt ≥ 65 kg) 8 w → PEG-IFNα-2b + LAM 24 w → LAM 28 w
2. LAM (100 mg/d)
Janssen HLA 2005 266 RCT 5 52 w 26 w 1. PEG-IFNα-2b (100 ug/w) + placebo
2. PEG-IFNα-2b (100 ug/w) + LAM (100 mg/d)
Buster E.H.C.J 2008 172 RCT 5 52 w 3.0 ± 0.8 y 1. PEG-IFNα-2b (100 ug/w) + placebo
2. PEG-IFNα-2b (100 ug/w) + LAM (100 mg/d)
Kaymakoglu S. 2007 48 RCT 2 48 w 24 w 1. PEG-IFNα-2b (1.5 ug/kg, 1/w)
2. PEG-IFNα-2b (1.5 ug/kg, 1/w) + LAM (100 mg/d)
Tian YL 2007 72 RCT 2 48 w 72 w 1. PEG-IFNα-2a (180 ug/w)
2. Conventional IFNα-2a (5 MU, 1/2 d)
Huang ZL 2010 50 NRCT 1 52 w 0 1. PEG-IFNα-2a (135 ug/w) 12 w → PEG-IFNα-2a + LAM (100 mg/d) 12 w → PEG-IFNα-2a 28 w
2. PEG-IFNα-2a 52 w
Cui JJ 2006 80 RCT 2 6 m 6 m 1. PEG-IFNα-2a (180 ug/w)
2. Conventional IFNα-2a (5 MU, 3/w)
Li ZQ 2010 74 NRCT 1 48 w 24 w 1. PEG-IFNα-2a (180 ug/w)
2. Conventional IFNα-2a (5 MU, 1/2 d)
Guan LJ 2006 32 RCT 2 24 w 6 m 1. PEG-IFNα-2a (180 ug/w)
2. Conventional IFNα-2b (5 MU, 1/2 d)
Shi XF 2006 27 NRCT 1 6 m 0 1. PEG-IFNα-2a (135-180 ug/w) + placebo
2. PEG-IFNα-2a (135-180 ug/w) + LAM (100 mg/d) 3 m → PEG-IFNα-2a 3 m
  1. PEG-IFNα-2a: pegylated interferon alpha-2a; LAM: lamivudine; RCT: randomized controlled trial; NRCT: nonrandomized controlled trial; d: days; w: weeks; m: months; y: years.